24-556 Phase III
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of anitocabtagene autoleucel (anito-cel) versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma (iMMagine-3)
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of anitocabtagene autoleucel (anito-cel) versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma (iMMagine-3)
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
A phase II study of ISABELA: isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies
Phase II study on Acalabrutinib and anti-CD20 antibody in Patients with Anti-MAG Mediated Neuropathy